Page last updated: 2024-11-13
i-antigen
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
I-antigen: used as a marker for well-differentiated leukemia cells; carbohydrate structure of immunodominant epitope is Galbeta1-4GlcNAcbeta1-3Galbeta1-4GlcNAcbeta1-3R which is very similar to that of sialyl SSEA-1 [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
ID Source | ID |
---|---|
PubMed CID | 73427349 |
CHEBI ID | 61610 |
MeSH ID | M0211517 |
Synonyms (10)
Synonym |
---|
i-antigen |
beta-d-galactosyl-(1->4)-n-acetyl-beta-d-glucosaminyl-(1->3)-beta-d-galactosyl-(1->4)-n-acetyl-beta-d-glucosaminyl-(1->3)-(1->3)-beta-d-galactosyl-(1->4)-beta-d-glucosyl-(1<->1')-ceramide |
CHEBI:61610 , |
galbeta1-4glcnacbeta1-3galbeta1-4glcnacbeta1-3galbeta1-4glcbeta1-1cer |
lacto-n-norhexaosylceramide |
(gal)3 (glc)1 (glcnac)2 (cer)1 |
nlc6cer |
EPITOPE ID:149545 |
beta-d-galp-(1->4)-beta-d-glcpnac-(1->3)-beta-d-galp-(1->4)-beta-d-glcpnac-(1->3)-beta-d-galp-(1->4)-beta-d-glcp-(1<->1')-cer |
Q28529700 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (36)
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 21 (58.33) | 18.7374 |
1990's | 3 (8.33) | 18.2507 |
2000's | 4 (11.11) | 29.6817 |
2010's | 7 (19.44) | 24.3611 |
2020's | 1 (2.78) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 31.87
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (31.87) All Compounds (24.57) |
Study Types
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 1 (2.50%) | 5.53% |
Reviews | 1 (2.50%) | 6.00% |
Case Studies | 1 (2.50%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 37 (92.50%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |